SurroMed and Biogen link up on MS (multiple sclerosis) deal
This article was originally published in Clinica
Executive Summary
SurroMed has entered into a two-year collaborative research agreement with Biogen to identify biological markers that could lead to diagnostic tests to guide and improve therapy for patients with multiple sclerosis (MS) and that may help develop new MS drugs.